Aspire Biopharma Holdings, Inc. (ASBP)
NASDAQ: ASBP · Real-Time Price · USD
7.85
+0.74 (10.41%)
At close: Aug 14, 2026, 4:00 PM EDT
7.58
-0.27 (-3.44%)
After-hours: Aug 14, 2026, 7:48 PM EDT

Aspire Biopharma Holdings Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-11.05-24.48-1.31-0.36-0.6
Other Amortization
9.68.02---
Stock-Based Compensation
0.1614.13---
Other Operating Activities
-6.01-3.13---
Change in Inventory
-0.33-0.25---
Change in Accounts Payable
-1.38-0.320.250.050.1
Change in Other Net Operating Assets
1.821.110.80.320.35
Operating Cash Flow
-7.19-4.92-0.270.01-0.14
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Sale (Purchase) of Intangibles
-----4.9
Investing Cash Flow
-----4.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Short-Term Debt Issued
-10.3---
Total Debt Issued
9.2510.3---
Short-Term Debt Repaid
--3.73---
Total Debt Repaid
-7.07-3.73---
Net Debt Issued (Repaid)
2.186.57---
Issuance of Common Stock
0.810.810.26-1
Other Financing Activities
-1.79-1.45--3.85
Financing Cash Flow
19.155.920.26-4.85

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
11.961-0.010.01-0.19

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Levered Free Cash Flow
21.415.39-0.68-0.19-
Unlevered Free Cash Flow
17.6212.7-0.62-0.19-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash Interest Paid
0.040.04---
Change in Working Capital
0.110.531.040.370.45
SEC Filings: 10-K · 10-Q